35results about How to "Improve learning and memory impairment" patented technology

The invention provides a scorpion venom heat-resisting polypeptide, and a preparing method and applications thereof, and belongs to the field of polypeptide and preparation thereof. The scorpion venom heat-resisting polypeptide which is safer is obtained by removing heat-resisting and heat-labile toxic components mainly from the scorpion venom of buthus martensii kirsch (BmK). The polypeptide is used for preventing and treating intractable epilepsy, Parkinson's disease (PD), Alzheimer's disease (AD), and other diseases, has a common function target, and has respective special medicine effects. Preparation of the polypeptide is stable in process, simple and controllable.

The tubiflorous desert cistanche preparation containing phenethyl alcohol glycoside contains echinacoside in 10-70 wt% and acteoside in 1-40 wt%. The preparation of the present invention may be applied as active component for preparing medicine treating and preventing senile dementia and for preparing medicine inhibiting platelet aggregation.

The invention belongs to the technical field of medicines, and relates to a novel method for preparing shiny-leaved yellowhorn total saponins from shiny-leaved yellowhorn and an application of the shiny-leaved yellowhorn total saponins. According to the method, a coarse extract of the shiny-leaved yellowhorn is directly separated and purified by a macroporous resin method to obtain shiny-leaved yellowhorn total saponins; the yield of the total saponins is over 5 percent, and the content of the total saponins in a product is over 60 percent and far higher than that in products prepared by other processes. The prepared shiny-leaved yellowhorn total saponins can be applied to preparation of medicines or health-care products for preventing and treating memory deterioration, hypophrenia and cranial nerve injury caused by neurodegenerative diseases and acute and chronic cerebral injury diseases, and can be used for treating cerebral diseases caused by alzheimer disease, acute disease and subacute stage of cerebral arterial thrombosis, vascular dementia and other ischemia and hypoxia of neurodegenerative diseases and acute and chronic cerebral injury diseases.

The invention relates to a shRNA (Short Hairpin Ribonucleic Acid) kit for treating an animal model suffered from an alzheimer disease. The kit internally comprises shRAN slow virus expression plasmid vector concentrated liquor capable of specifically suppressing a caspase-3 gene, and shRAN slow virus expression plasmid vector concentrated liquor as negative control, wherein the shRAN comprises sequences of SEQ ID No.1 and SEQ ID NO.2 in a sequence table. Compared with other means, the shRAN sequence or a reagent obtained therefrom can specifically and conveniently suppress the expression of disease-related proteins at high efficiency when entering the body of the animal model in a certain manner and lead disease-related genes to be silent, thereby achieving the treatment purpose; and therefore, the kit provided by the invention can be used for gene therapy for the animal model suffered from the alzheimer diseases.

A puerarin derivative and a synthetic method and an application thereof belong to the field of cerebrovascular diseases. Selectivity of a vascular dementia therapeutic target is improved by decorating puerarin. The puerarin derivative is indicated through a formula (1) which is as follows. By means of a chemical synthetic method, products are applied to treatment of vascular dementia. Fat solubility and water solubility of the puerarin are improved, receptor selectivity of the puerarin is improved, osmotic pressures inside and outside brain cells are balanced, cellular swelling caused by inflammatory injury is improved, a pharmacologic action of the puerarin itself of improving microcirculation and cholinergic nerve system functions is highlighted, and learning and memory disorders caused by damage caused by ischemia reperfusion are avoided.

The invention relates to the field of drugs, in particular to a carbamidine derivative containing a furan structure and a composition of the carbamidine derivative. The derivative and the compositionthereof can be used for preparing drugs for treating a pathologic characteristic disease with an indoleamine 2,3-dioxygenase mediated tryptophan metabolic pathway. The invention further relates to a method for preparing the derivative and an intermediate thereof.

The invention relates to an effective part extracted from the traditional Chinese medicine pseudobulubs cremastrae seu pleiones (with plant root in Pleione bulbocodioides and Pleione yunnanensis), a preparation method, and application thereof in treatment of senile dementia and vascular dementia. Animal tests prove that the effective part can obviously improve the learning and memory disorder of scopolamine induced mouse cholinergic impairment analog dementia animal models, can enhance the recognition capability of common carotid artery ligation induced vascular dementia rats on new objects, and can improve the object recognition disorder and spatial learning and memory disorder caused by vascular dementia. With antioxidant capacity, the pseudobulubs cremastrae seu pleiones' effective part can reach the effect of delaying degenerative changes of nerve cells by reducing oxidative damage response.

The invention relates to the technical field of stem cells, in particular to umbilical cord mesenchymal stem cell modified by a Nrf2 gene as well as a preparation method and an application thereof. The invention discloses the umbilical cord mesenchymal stem cell modified by the Nrf2 gene. The umbilical cord mesenchymal stem cell modified by the Nrf2 gene is the umbilical cord mesenchymal stem cellfor overexpression of the Nrf2. The resistance of the Nfr2 gene modified UCMSC to nerve injury is enhanced, the oxidative stress can be effectively antagonized, and the Nfr2 gene modified UCMSC can effectively promote the UCMSC to be converted into neural stem cells compared with the unmodified UCMSC. The UCMSC modified by the Nfr2 gene is transplanted into a dementia mouse body; the Nfr2 gene modified UCMSC can significantly improve learning and memory impairment of dementia mice, protect oxidative damage of brain tissues of the dementia mice, reduce activity of hippocampus AChE and NO in the brains of the dementia mice and inhibit release of inflammatory factors in the hippocampus tissues in the brains of the senile dementia mice. The technical support is provided for preparing a medicine for treating senile dementia by the stem cell.

The invention discloses a pabular health tea electuary for nourishing brain, which belongs to the field of nutritious foods and has the advantages of good effect and rapid effect. The pabular health tea electuary is made from the raw materials such as sealwort, mulberry, taurine, gastrodia elata, black tea and the like, has the functions of supporting body resistance, reinforcing qi, nourishing blood, promoting blood circulation, removing blood stasis and nourishing brain, and has the advantages of good effect and rapid effect.

The invention relates to a preparation method of a folium cortex eucommiae effective position. The method comprises the following steps of performing ultrasound or scattered extraction on crushed folium cortex eucommiae by 30 to 80-percent ethyl alcohol; after the extraction liquid concentration, performing adsorption by macroporous adsorption resin; then, sequentially performing water washing, 20-60-percent ethyl alcohol gradient elution; merging elution liquid collected in gradient elution; performing concentration and drying to obtain the folium cortex eucommiae effective position. Through experiments, the folium cortex eucommiae effective position has the obvious protection effect on the mouse brain nerve DNA injury induced by alcohol; through the protection mechanism, the anti-oxidization function of the mouse brain tissues can be enhanced; the body is protected from further injury by free radicals; the folium cortex eucommiae effective position can be used for preparing brain nerve protection health care products, food or medicine.

The invention relates to a new application of split iridoid derivatives in the field of pharmacy, in particular to the application of split ring iridoid derivatives in the preparation of drugs for preventing and treating neurodegenerative diseases. In the treatment of neurodegenerative diseases, this type of product can significantly increase the activity of nerve cells and exert an obvious neuroprotective effect. The protective effect on the SH‑SY5Y cell model damaged by hydrogen peroxide is stronger than that of loganin, Morroniside can significantly improve the learning and memory impairment of aging individuals, and significantly increase the total antioxidant capacity in brain tissue.

The invention belongs to the technical field of medicines, and relates to a novel method for preparing shiny-leaved yellowhorn total saponins from shiny-leaved yellowhorn and an application of the shiny-leaved yellowhorn total saponins. According to the method, a coarse extract of the shiny-leaved yellowhorn is directly separated and purified by a macroporous resin method to obtain shiny-leaved yellowhorn total saponins; the yield of the total saponins is over 5 percent, and the content of the total saponins in a product is over 60 percent and far higher than that in products prepared by other processes. The prepared shiny-leaved yellowhorn total saponins can be applied to preparation of medicines or health-care products for preventing and treating memory deterioration, hypophrenia and cranial nerve injury caused by neurodegenerative diseases and acute and chronic cerebral injury diseases, and can be used for treating cerebral diseases caused by alzheimer disease, acute disease and subacute stage of cerebral arterial thrombosis, vascular dementia and other ischemia and hypoxia of neurodegenerative diseases and acute and chronic cerebral injury diseases.

A puerarin derivative and a synthetic method and an application thereof belong to the field of cerebrovascular diseases. Selectivity of a vascular dementia therapeutic target is improved by decorating puerarin. The puerarin derivative is indicated through a formula (1) which is as follows. By means of a chemical synthetic method, products are applied to treatment of vascular dementia. Fat solubility and water solubility of the puerarin are improved, receptor selectivity of the puerarin is improved, osmotic pressures inside and outside brain cells are balanced, cellular swelling caused by inflammatory injury is improved, a pharmacologic action of the puerarin itself of improving microcirculation and cholinergic nerve system functions is highlighted, and learning and memory disorders caused by damage caused by ischemia reperfusion are avoided.

The invention provides a traditional Chinese medicine composition for improving memory and mild cognitive impairment. The traditional Chinese medicine composition comprises 40-80 parts of thinleaf milkwort root-bark, 40-80 parts of grass leaf sweetflag rhizome, 40-80 parts of ginseng, 80-120 parts of tall gastrodia tuber, 80-120 parts of papermulberry fruit, 80-120 parts of ginkgo leaves and 0.01-3 parts of borneol. The traditional Chinese medicine composition can achieve the effects of obviously increasing the number density and surface density of synapse of the molecular layer of mouse hippocampal CA1, obviously enhancing the SOD activities of central cerebral cortex and hippocampus, reducing the content of lipofuscin of the neuron, obviously improving the learning and memory impairment of spontaneous senile dementia model mice, obviously enhancing the activity and fiber density of NOS1 of the central cerebral cortex and hippocampus and obviously up-regulating the contents of SS, AVP and ACTH of the cerebral cortex and hippocampus, especially the content of SS. The traditional Chinese medicine composition can achieve the effect of obviously improving the clinical symptoms of memory and cognitive impairment and has definite curative effects and great application prospects.

The invention relates to a shRNA (Short Hairpin Ribonucleic Acid) kit for treating an animal model suffered from an alzheimer disease. The kit internally comprises shRAN slow virus expression plasmid vector concentrated liquor capable of specifically suppressing a caspase-3 gene, and shRAN slow virus expression plasmid vector concentrated liquor as negative control, wherein the shRAN comprises sequences of SEQ ID No.1 and SEQ ID NO.2 in a sequence table. Compared with other means, the shRAN sequence or a reagent obtained therefrom can specifically and conveniently suppress the expression of disease-related proteins at high efficiency when entering the body of the animal model in a certain manner and lead disease-related genes to be silent, thereby achieving the treatment purpose; and therefore, the kit provided by the invention can be used for gene therapy for the animal model suffered from the alzheimer diseases.

The present invention relates to the effective part extracted from the traditional Chinese medicine Baiji, its preparation method and its use in treating Alzheimer's Disease (AD) and vascular dementia (VD). It has been confirmed by animal experiments that this effective part can significantly improve the memory acquisition impairment of scopolamine-induced cholinergic impairment in dementia mice; improve the space of AD rats induced by intracerebroventricular injection of Aβ and VD rats induced by permanent ligation of bilateral common carotid arteries. Learning and memory impairment has obvious improvement effect on animal learning and memory impairment.

The present invention relates to the field of medicines, and in particular to an imino-urea derivative containing a furan structure and a composition thereof. The derivative and the composition thereof can be used in the manufacture of a medicament for treating a disease pathologically characterized by indoleamine 2,3-dioxygenase-mediated tryptophan metabolic pathway. The present invention also relates to a method for preparing the derivative and an intermediate thereof.

A Chinese medicine for treating senile dementia, dizziness, disturbed sleep, etc is prepared from fleece flower root, lotus leaf, cistanche, earthworm and uniflower swisscentaury root through respective extracting, and proportional mixing.

The invention discloses a traditional Chinese medicine composition for preventing and treating vascular dementia. The traditional Chinese medicine composition for preventing and treating vascular dementia comprises ginseng, gastrodia elata, Euonymus alatus and Ligusticum wallichii. The composition can be prepared into Chinese herbal preparation crude drug for preventing and treating vascular dementia. The ginseng and the Ligusticum wallichii are extracted with alcohol, the gastrodia elata and the Euonymus alatus are extracted with water, the obtained alcohol extract and the obtained water extract are mixed, the mixture is dried under vacuum and then is pulverized to obtain the final product, and the composition can be directly taken orally or is prepared into other dosage forms such as granules, capsules, soft capsules, electuaries, pills and decocted extracts. The composition is completely prepared from natural medicinal plants, does not contain hormones, and does not contain other chemical synthetic products such as pigment, and even if a patient orally takes the composition continuously, no toxic and side effect is performed on the human body. The traditional Chinese medicine composition contains various easily absorbable ingredients such as ginsenoside, chuanxiongol, chuanxiongzine, gastrodin and quercetin, can be effectively used for treating the vascular dementia, increases cerebral blood flow, reduces cerebral vascular resistance, improves body immunocompetence, and has effects of tonifying deficiency, promoting intelligence, suppressing the hyperactive liver, subsiding Yang, dispelling blood stasis and dredging collaterals.

The invention discloses TAT-LBD-PEP fusion protein and application of the TAT-LBD-PEP fusion protein in treatment of central nervous system lesion. The TAT-LBD-PEP fusion protein is combined with myelin inhibiting factors MAG, Nogo-66 and OMgp, accordingly the axon regenerative capacity is promoted through antagonism PirB effect, and the TAT-LBD-PEP fusion protein has the advantages of being high transduction efficiency and easily transmitting a blood-spinal barrier and a blood brain barrier, can transduce targeting to a hurt region and has the enrichment effect on an ischemic region. The problems that additional harm of nervous tissues is caused by the protein injection in a micro-injection mode or other injection modes and macromolecule cannot transmit the blood-spinal barrier and the blood brain barrier are solved, and the shortcoming that corresponding biological concentration cannot be met is overcome, and the targeting is transduced to the ischemic region through a ligand binding domain (LBD). The TAT-LBD-PEP fusion protein can be prepared in large-scale mode, is low in cost and high in activity, and is used for treatment of various brain and spinal cord injury including cerebral ischemia hypoxia, cerebral hemorrhage, cerebral trauma, spinal cord injury and the like and promoting regeneration of nervous tissues and neural functional recovery.